These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20406182)

  • 21. Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation.
    Naumann M; Pal A; Goswami A; Lojewski X; Japtok J; Vehlow A; Naujock M; Günther R; Jin M; Stanslowsky N; Reinhardt P; Sterneckert J; Frickenhaus M; Pan-Montojo F; Storkebaum E; Poser I; Freischmidt A; Weishaupt JH; Holzmann K; Troost D; Ludolph AC; Boeckers TM; Liebau S; Petri S; Cordes N; Hyman AA; Wegner F; Grill SW; Weis J; Storch A; Hermann A
    Nat Commun; 2018 Jan; 9(1):335. PubMed ID: 29362359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
    Baloh RH
    Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA-binding proteins and RNA metabolism: a new scenario in the pathogenesis of Amyotrophic lateral sclerosis.
    Colombrita C; Onesto E; Tiloca C; Ticozzi N; Silani V; Ratti A
    Arch Ital Biol; 2011 Mar; 149(1):83-99. PubMed ID: 21412718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Conjoint pathological cascades mediated by RNA-binding proteins, TDP-43, FUS and ataxin-2].
    Ito D
    Rinsho Shinkeigaku; 2012; 52(11):1221-3. PubMed ID: 23196570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyotrophic lateral sclerosis-linked mutant VAPB enhances TDP-43-induced motor neuronal toxicity.
    Suzuki H; Matsuoka M
    J Neurochem; 2011 Dec; 119(5):1099-107. PubMed ID: 21933185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues.
    Watanabe M; Dykes-Hoberg M; Culotta VC; Price DL; Wong PC; Rothstein JD
    Neurobiol Dis; 2001 Dec; 8(6):933-41. PubMed ID: 11741389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant regulation of DNA methylation in amyotrophic lateral sclerosis: a new target of disease mechanisms.
    Martin LJ; Wong M
    Neurotherapeutics; 2013 Oct; 10(4):722-33. PubMed ID: 23900692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of RNA processing in the pathogenesis of motor neuron degeneration.
    Bäumer D; Ansorge O; Almeida M; Talbot K
    Expert Rev Mol Med; 2010 Jul; 12():e21. PubMed ID: 20642879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular basis of amyotrophic lateral sclerosis.
    Liscic RM; Breljak D
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):370-2. PubMed ID: 20655970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS).
    Volkening K; Leystra-Lantz C; Yang W; Jaffee H; Strong MJ
    Brain Res; 2009 Dec; 1305():168-82. PubMed ID: 19815002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TDP-43 and FUS/TLS: sending a complex message about messenger RNA in amyotrophic lateral sclerosis?
    Strong MJ; Volkening K
    FEBS J; 2011 Oct; 278(19):3569-77. PubMed ID: 21810174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disrupted neuronal trafficking in amyotrophic lateral sclerosis.
    Burk K; Pasterkamp RJ
    Acta Neuropathol; 2019 Jun; 137(6):859-877. PubMed ID: 30721407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TDP-43 in differential diagnosis of motor neuron disorders.
    Dickson DW; Josephs KA; Amador-Ortiz C
    Acta Neuropathol; 2007 Jul; 114(1):71-9. PubMed ID: 17569066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo stress granule misprocessing evidenced in a FUS knock-in ALS mouse model.
    Zhang X; Wang F; Hu Y; Chen R; Meng D; Guo L; Lv H; Guan J; Jia Y
    Brain; 2020 May; 143(5):1350-1367. PubMed ID: 32358598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?
    van den Heuvel DM; Harschnitz O; van den Berg LH; Pasterkamp RJ
    Trends Mol Med; 2014 Jan; 20(1):25-35. PubMed ID: 24140266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A microfluidic approach to rescue ALS motor neuron degeneration using rapamycin.
    Chennampally P; Sayed-Zahid A; Soundararajan P; Sharp J; Cox GA; Collins SD; Smith RL
    Sci Rep; 2021 Sep; 11(1):18168. PubMed ID: 34518579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent progress in ALS research: ALS and TDP-43].
    Kuzuhara S
    Rinsho Shinkeigaku; 2008 Sep; 48(9):625-33. PubMed ID: 19048944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis.
    Shang Y; Huang EJ
    Brain Res; 2016 Sep; 1647():65-78. PubMed ID: 27033831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleo-cytoplasmic transport of TDP-43 studied in real time: impaired microglia function leads to axonal spreading of TDP-43 in degenerating motor neurons.
    Svahn AJ; Don EK; Badrock AP; Cole NJ; Graeber MB; Yerbury JJ; Chung R; Morsch M
    Acta Neuropathol; 2018 Sep; 136(3):445-459. PubMed ID: 29943193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS.
    Yamashita T; Kwak S
    Neurosci Res; 2019 Jul; 144():4-13. PubMed ID: 29944911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.